The expression of Midkine gene in patients with acute myeloid leukemia and its significance
Abstract Midkine (MK) is a heparin-binding growth factor and a product of a retinoic acid-responsive gene. Midkine is overexpressed in many carcinomas and thought to play an important role in carcinogenesis. However, no studies have been focused on the role of MK in AML. This study sought to evaluat...
Ausführliche Beschreibung
Autor*in: |
Hammam, Amira A. [verfasserIn] El Dahshan, Dina H. [verfasserIn] Metwally, Hassan M. [verfasserIn] El Feky, Mohamed A. [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2013 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
Enthalten in: Comparative haematology international - London : Springer, 1991, 23(2013), 3 vom: 24. Jan., Seite 749-753 |
---|---|
Übergeordnetes Werk: |
volume:23 ; year:2013 ; number:3 ; day:24 ; month:01 ; pages:749-753 |
Links: |
---|
DOI / URN: |
10.1007/s00580-013-1680-1 |
---|
Katalog-ID: |
SPR007225504 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR007225504 | ||
003 | DE-627 | ||
005 | 20230519204820.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201005s2013 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s00580-013-1680-1 |2 doi | |
035 | |a (DE-627)SPR007225504 | ||
035 | |a (SPR)s00580-013-1680-1-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q ASE |
082 | 0 | 4 | |a 610 |q ASE |
100 | 1 | |a Hammam, Amira A. |e verfasserin |4 aut | |
245 | 1 | 4 | |a The expression of Midkine gene in patients with acute myeloid leukemia and its significance |
264 | 1 | |c 2013 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Abstract Midkine (MK) is a heparin-binding growth factor and a product of a retinoic acid-responsive gene. Midkine is overexpressed in many carcinomas and thought to play an important role in carcinogenesis. However, no studies have been focused on the role of MK in AML. This study sought to evaluate the expression of MK among AML patients to explore possible correlation between MK expression and different clinicopathologic variables in an attempt to determine the prognostic value of MK expression. Mononuclear cells were separated from samples of 50 newly diagnosed cases of AML; 10 healthy volunteers were included in this study as control group. The reverse transcription polymerase chain reaction method was used to examine the expression of MK mRNA in mononuclear cells. Midkine gene mRNA expression rate was significantly higher in AML patients when compared to control group (p < 0.001); comparing Midkine expression in patients with different clinical and laboratory findings was of no statistical significance (p > 0.05). Moreover, Midkine expression was significantly higher in patients that did not achieve complete remission compared to those who succeeded to achieve one (p < 0.001). Midkine may play an important role in the tumorigenesis of AML, and evaluation of MK expression may prove to be useful for predicting response to treatment. | ||
650 | 4 | |a Midkine gene |7 (dpeaa)DE-He213 | |
650 | 4 | |a Acute myeloid leukemia |7 (dpeaa)DE-He213 | |
650 | 4 | |a Gene expression |7 (dpeaa)DE-He213 | |
700 | 1 | |a El Dahshan, Dina H. |e verfasserin |4 aut | |
700 | 1 | |a Metwally, Hassan M. |e verfasserin |4 aut | |
700 | 1 | |a El Feky, Mohamed A. |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Comparative haematology international |d London : Springer, 1991 |g 23(2013), 3 vom: 24. Jan., Seite 749-753 |w (DE-627)559430590 |w (DE-600)2413027-8 |x 1433-2973 |7 nnns |
773 | 1 | 8 | |g volume:23 |g year:2013 |g number:3 |g day:24 |g month:01 |g pages:749-753 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00580-013-1680-1 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_70 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_90 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_100 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_120 | ||
912 | |a GBV_ILN_152 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_171 | ||
912 | |a GBV_ILN_187 | ||
912 | |a GBV_ILN_224 | ||
912 | |a GBV_ILN_250 | ||
912 | |a GBV_ILN_281 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_370 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_702 | ||
951 | |a AR | ||
952 | |d 23 |j 2013 |e 3 |b 24 |c 01 |h 749-753 |
author_variant |
a a h aa aah d d h e ddh ddhe h m m hm hmm f m a e fma fmae |
---|---|
matchkey_str |
article:14332973:2013----::hepesoomdieeenainsihctmeodek |
hierarchy_sort_str |
2013 |
publishDate |
2013 |
allfields |
10.1007/s00580-013-1680-1 doi (DE-627)SPR007225504 (SPR)s00580-013-1680-1-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE Hammam, Amira A. verfasserin aut The expression of Midkine gene in patients with acute myeloid leukemia and its significance 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Midkine (MK) is a heparin-binding growth factor and a product of a retinoic acid-responsive gene. Midkine is overexpressed in many carcinomas and thought to play an important role in carcinogenesis. However, no studies have been focused on the role of MK in AML. This study sought to evaluate the expression of MK among AML patients to explore possible correlation between MK expression and different clinicopathologic variables in an attempt to determine the prognostic value of MK expression. Mononuclear cells were separated from samples of 50 newly diagnosed cases of AML; 10 healthy volunteers were included in this study as control group. The reverse transcription polymerase chain reaction method was used to examine the expression of MK mRNA in mononuclear cells. Midkine gene mRNA expression rate was significantly higher in AML patients when compared to control group (p < 0.001); comparing Midkine expression in patients with different clinical and laboratory findings was of no statistical significance (p > 0.05). Moreover, Midkine expression was significantly higher in patients that did not achieve complete remission compared to those who succeeded to achieve one (p < 0.001). Midkine may play an important role in the tumorigenesis of AML, and evaluation of MK expression may prove to be useful for predicting response to treatment. Midkine gene (dpeaa)DE-He213 Acute myeloid leukemia (dpeaa)DE-He213 Gene expression (dpeaa)DE-He213 El Dahshan, Dina H. verfasserin aut Metwally, Hassan M. verfasserin aut El Feky, Mohamed A. verfasserin aut Enthalten in Comparative haematology international London : Springer, 1991 23(2013), 3 vom: 24. Jan., Seite 749-753 (DE-627)559430590 (DE-600)2413027-8 1433-2973 nnns volume:23 year:2013 number:3 day:24 month:01 pages:749-753 https://dx.doi.org/10.1007/s00580-013-1680-1 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 23 2013 3 24 01 749-753 |
spelling |
10.1007/s00580-013-1680-1 doi (DE-627)SPR007225504 (SPR)s00580-013-1680-1-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE Hammam, Amira A. verfasserin aut The expression of Midkine gene in patients with acute myeloid leukemia and its significance 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Midkine (MK) is a heparin-binding growth factor and a product of a retinoic acid-responsive gene. Midkine is overexpressed in many carcinomas and thought to play an important role in carcinogenesis. However, no studies have been focused on the role of MK in AML. This study sought to evaluate the expression of MK among AML patients to explore possible correlation between MK expression and different clinicopathologic variables in an attempt to determine the prognostic value of MK expression. Mononuclear cells were separated from samples of 50 newly diagnosed cases of AML; 10 healthy volunteers were included in this study as control group. The reverse transcription polymerase chain reaction method was used to examine the expression of MK mRNA in mononuclear cells. Midkine gene mRNA expression rate was significantly higher in AML patients when compared to control group (p < 0.001); comparing Midkine expression in patients with different clinical and laboratory findings was of no statistical significance (p > 0.05). Moreover, Midkine expression was significantly higher in patients that did not achieve complete remission compared to those who succeeded to achieve one (p < 0.001). Midkine may play an important role in the tumorigenesis of AML, and evaluation of MK expression may prove to be useful for predicting response to treatment. Midkine gene (dpeaa)DE-He213 Acute myeloid leukemia (dpeaa)DE-He213 Gene expression (dpeaa)DE-He213 El Dahshan, Dina H. verfasserin aut Metwally, Hassan M. verfasserin aut El Feky, Mohamed A. verfasserin aut Enthalten in Comparative haematology international London : Springer, 1991 23(2013), 3 vom: 24. Jan., Seite 749-753 (DE-627)559430590 (DE-600)2413027-8 1433-2973 nnns volume:23 year:2013 number:3 day:24 month:01 pages:749-753 https://dx.doi.org/10.1007/s00580-013-1680-1 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 23 2013 3 24 01 749-753 |
allfields_unstemmed |
10.1007/s00580-013-1680-1 doi (DE-627)SPR007225504 (SPR)s00580-013-1680-1-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE Hammam, Amira A. verfasserin aut The expression of Midkine gene in patients with acute myeloid leukemia and its significance 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Midkine (MK) is a heparin-binding growth factor and a product of a retinoic acid-responsive gene. Midkine is overexpressed in many carcinomas and thought to play an important role in carcinogenesis. However, no studies have been focused on the role of MK in AML. This study sought to evaluate the expression of MK among AML patients to explore possible correlation between MK expression and different clinicopathologic variables in an attempt to determine the prognostic value of MK expression. Mononuclear cells were separated from samples of 50 newly diagnosed cases of AML; 10 healthy volunteers were included in this study as control group. The reverse transcription polymerase chain reaction method was used to examine the expression of MK mRNA in mononuclear cells. Midkine gene mRNA expression rate was significantly higher in AML patients when compared to control group (p < 0.001); comparing Midkine expression in patients with different clinical and laboratory findings was of no statistical significance (p > 0.05). Moreover, Midkine expression was significantly higher in patients that did not achieve complete remission compared to those who succeeded to achieve one (p < 0.001). Midkine may play an important role in the tumorigenesis of AML, and evaluation of MK expression may prove to be useful for predicting response to treatment. Midkine gene (dpeaa)DE-He213 Acute myeloid leukemia (dpeaa)DE-He213 Gene expression (dpeaa)DE-He213 El Dahshan, Dina H. verfasserin aut Metwally, Hassan M. verfasserin aut El Feky, Mohamed A. verfasserin aut Enthalten in Comparative haematology international London : Springer, 1991 23(2013), 3 vom: 24. Jan., Seite 749-753 (DE-627)559430590 (DE-600)2413027-8 1433-2973 nnns volume:23 year:2013 number:3 day:24 month:01 pages:749-753 https://dx.doi.org/10.1007/s00580-013-1680-1 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 23 2013 3 24 01 749-753 |
allfieldsGer |
10.1007/s00580-013-1680-1 doi (DE-627)SPR007225504 (SPR)s00580-013-1680-1-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE Hammam, Amira A. verfasserin aut The expression of Midkine gene in patients with acute myeloid leukemia and its significance 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Midkine (MK) is a heparin-binding growth factor and a product of a retinoic acid-responsive gene. Midkine is overexpressed in many carcinomas and thought to play an important role in carcinogenesis. However, no studies have been focused on the role of MK in AML. This study sought to evaluate the expression of MK among AML patients to explore possible correlation between MK expression and different clinicopathologic variables in an attempt to determine the prognostic value of MK expression. Mononuclear cells were separated from samples of 50 newly diagnosed cases of AML; 10 healthy volunteers were included in this study as control group. The reverse transcription polymerase chain reaction method was used to examine the expression of MK mRNA in mononuclear cells. Midkine gene mRNA expression rate was significantly higher in AML patients when compared to control group (p < 0.001); comparing Midkine expression in patients with different clinical and laboratory findings was of no statistical significance (p > 0.05). Moreover, Midkine expression was significantly higher in patients that did not achieve complete remission compared to those who succeeded to achieve one (p < 0.001). Midkine may play an important role in the tumorigenesis of AML, and evaluation of MK expression may prove to be useful for predicting response to treatment. Midkine gene (dpeaa)DE-He213 Acute myeloid leukemia (dpeaa)DE-He213 Gene expression (dpeaa)DE-He213 El Dahshan, Dina H. verfasserin aut Metwally, Hassan M. verfasserin aut El Feky, Mohamed A. verfasserin aut Enthalten in Comparative haematology international London : Springer, 1991 23(2013), 3 vom: 24. Jan., Seite 749-753 (DE-627)559430590 (DE-600)2413027-8 1433-2973 nnns volume:23 year:2013 number:3 day:24 month:01 pages:749-753 https://dx.doi.org/10.1007/s00580-013-1680-1 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 23 2013 3 24 01 749-753 |
allfieldsSound |
10.1007/s00580-013-1680-1 doi (DE-627)SPR007225504 (SPR)s00580-013-1680-1-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE Hammam, Amira A. verfasserin aut The expression of Midkine gene in patients with acute myeloid leukemia and its significance 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Midkine (MK) is a heparin-binding growth factor and a product of a retinoic acid-responsive gene. Midkine is overexpressed in many carcinomas and thought to play an important role in carcinogenesis. However, no studies have been focused on the role of MK in AML. This study sought to evaluate the expression of MK among AML patients to explore possible correlation between MK expression and different clinicopathologic variables in an attempt to determine the prognostic value of MK expression. Mononuclear cells were separated from samples of 50 newly diagnosed cases of AML; 10 healthy volunteers were included in this study as control group. The reverse transcription polymerase chain reaction method was used to examine the expression of MK mRNA in mononuclear cells. Midkine gene mRNA expression rate was significantly higher in AML patients when compared to control group (p < 0.001); comparing Midkine expression in patients with different clinical and laboratory findings was of no statistical significance (p > 0.05). Moreover, Midkine expression was significantly higher in patients that did not achieve complete remission compared to those who succeeded to achieve one (p < 0.001). Midkine may play an important role in the tumorigenesis of AML, and evaluation of MK expression may prove to be useful for predicting response to treatment. Midkine gene (dpeaa)DE-He213 Acute myeloid leukemia (dpeaa)DE-He213 Gene expression (dpeaa)DE-He213 El Dahshan, Dina H. verfasserin aut Metwally, Hassan M. verfasserin aut El Feky, Mohamed A. verfasserin aut Enthalten in Comparative haematology international London : Springer, 1991 23(2013), 3 vom: 24. Jan., Seite 749-753 (DE-627)559430590 (DE-600)2413027-8 1433-2973 nnns volume:23 year:2013 number:3 day:24 month:01 pages:749-753 https://dx.doi.org/10.1007/s00580-013-1680-1 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 23 2013 3 24 01 749-753 |
language |
English |
source |
Enthalten in Comparative haematology international 23(2013), 3 vom: 24. Jan., Seite 749-753 volume:23 year:2013 number:3 day:24 month:01 pages:749-753 |
sourceStr |
Enthalten in Comparative haematology international 23(2013), 3 vom: 24. Jan., Seite 749-753 volume:23 year:2013 number:3 day:24 month:01 pages:749-753 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
Midkine gene Acute myeloid leukemia Gene expression |
dewey-raw |
610 |
isfreeaccess_bool |
false |
container_title |
Comparative haematology international |
authorswithroles_txt_mv |
Hammam, Amira A. @@aut@@ El Dahshan, Dina H. @@aut@@ Metwally, Hassan M. @@aut@@ El Feky, Mohamed A. @@aut@@ |
publishDateDaySort_date |
2013-01-24T00:00:00Z |
hierarchy_top_id |
559430590 |
dewey-sort |
3610 |
id |
SPR007225504 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR007225504</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519204820.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201005s2013 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s00580-013-1680-1</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR007225504</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s00580-013-1680-1-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Hammam, Amira A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The expression of Midkine gene in patients with acute myeloid leukemia and its significance</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Midkine (MK) is a heparin-binding growth factor and a product of a retinoic acid-responsive gene. Midkine is overexpressed in many carcinomas and thought to play an important role in carcinogenesis. However, no studies have been focused on the role of MK in AML. This study sought to evaluate the expression of MK among AML patients to explore possible correlation between MK expression and different clinicopathologic variables in an attempt to determine the prognostic value of MK expression. Mononuclear cells were separated from samples of 50 newly diagnosed cases of AML; 10 healthy volunteers were included in this study as control group. The reverse transcription polymerase chain reaction method was used to examine the expression of MK mRNA in mononuclear cells. Midkine gene mRNA expression rate was significantly higher in AML patients when compared to control group (p < 0.001); comparing Midkine expression in patients with different clinical and laboratory findings was of no statistical significance (p > 0.05). Moreover, Midkine expression was significantly higher in patients that did not achieve complete remission compared to those who succeeded to achieve one (p < 0.001). Midkine may play an important role in the tumorigenesis of AML, and evaluation of MK expression may prove to be useful for predicting response to treatment.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Midkine gene</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Acute myeloid leukemia</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gene expression</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">El Dahshan, Dina H.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Metwally, Hassan M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">El Feky, Mohamed A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Comparative haematology international</subfield><subfield code="d">London : Springer, 1991</subfield><subfield code="g">23(2013), 3 vom: 24. Jan., Seite 749-753</subfield><subfield code="w">(DE-627)559430590</subfield><subfield code="w">(DE-600)2413027-8</subfield><subfield code="x">1433-2973</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:23</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:3</subfield><subfield code="g">day:24</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:749-753</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s00580-013-1680-1</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">23</subfield><subfield code="j">2013</subfield><subfield code="e">3</subfield><subfield code="b">24</subfield><subfield code="c">01</subfield><subfield code="h">749-753</subfield></datafield></record></collection>
|
author |
Hammam, Amira A. |
spellingShingle |
Hammam, Amira A. ddc 610 misc Midkine gene misc Acute myeloid leukemia misc Gene expression The expression of Midkine gene in patients with acute myeloid leukemia and its significance |
authorStr |
Hammam, Amira A. |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)559430590 |
format |
electronic Article |
dewey-ones |
610 - Medicine & health |
delete_txt_mv |
keep |
author_role |
aut aut aut aut |
collection |
springer |
remote_str |
true |
illustrated |
Not Illustrated |
issn |
1433-2973 |
topic_title |
610 ASE The expression of Midkine gene in patients with acute myeloid leukemia and its significance Midkine gene (dpeaa)DE-He213 Acute myeloid leukemia (dpeaa)DE-He213 Gene expression (dpeaa)DE-He213 |
topic |
ddc 610 misc Midkine gene misc Acute myeloid leukemia misc Gene expression |
topic_unstemmed |
ddc 610 misc Midkine gene misc Acute myeloid leukemia misc Gene expression |
topic_browse |
ddc 610 misc Midkine gene misc Acute myeloid leukemia misc Gene expression |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Comparative haematology international |
hierarchy_parent_id |
559430590 |
dewey-tens |
610 - Medicine & health |
hierarchy_top_title |
Comparative haematology international |
isfreeaccess_txt |
false |
familylinks_str_mv |
(DE-627)559430590 (DE-600)2413027-8 |
title |
The expression of Midkine gene in patients with acute myeloid leukemia and its significance |
ctrlnum |
(DE-627)SPR007225504 (SPR)s00580-013-1680-1-e |
title_full |
The expression of Midkine gene in patients with acute myeloid leukemia and its significance |
author_sort |
Hammam, Amira A. |
journal |
Comparative haematology international |
journalStr |
Comparative haematology international |
lang_code |
eng |
isOA_bool |
false |
dewey-hundreds |
600 - Technology |
recordtype |
marc |
publishDateSort |
2013 |
contenttype_str_mv |
txt |
container_start_page |
749 |
author_browse |
Hammam, Amira A. El Dahshan, Dina H. Metwally, Hassan M. El Feky, Mohamed A. |
container_volume |
23 |
class |
610 ASE |
format_se |
Elektronische Aufsätze |
author-letter |
Hammam, Amira A. |
doi_str_mv |
10.1007/s00580-013-1680-1 |
dewey-full |
610 |
author2-role |
verfasserin |
title_sort |
expression of midkine gene in patients with acute myeloid leukemia and its significance |
title_auth |
The expression of Midkine gene in patients with acute myeloid leukemia and its significance |
abstract |
Abstract Midkine (MK) is a heparin-binding growth factor and a product of a retinoic acid-responsive gene. Midkine is overexpressed in many carcinomas and thought to play an important role in carcinogenesis. However, no studies have been focused on the role of MK in AML. This study sought to evaluate the expression of MK among AML patients to explore possible correlation between MK expression and different clinicopathologic variables in an attempt to determine the prognostic value of MK expression. Mononuclear cells were separated from samples of 50 newly diagnosed cases of AML; 10 healthy volunteers were included in this study as control group. The reverse transcription polymerase chain reaction method was used to examine the expression of MK mRNA in mononuclear cells. Midkine gene mRNA expression rate was significantly higher in AML patients when compared to control group (p < 0.001); comparing Midkine expression in patients with different clinical and laboratory findings was of no statistical significance (p > 0.05). Moreover, Midkine expression was significantly higher in patients that did not achieve complete remission compared to those who succeeded to achieve one (p < 0.001). Midkine may play an important role in the tumorigenesis of AML, and evaluation of MK expression may prove to be useful for predicting response to treatment. |
abstractGer |
Abstract Midkine (MK) is a heparin-binding growth factor and a product of a retinoic acid-responsive gene. Midkine is overexpressed in many carcinomas and thought to play an important role in carcinogenesis. However, no studies have been focused on the role of MK in AML. This study sought to evaluate the expression of MK among AML patients to explore possible correlation between MK expression and different clinicopathologic variables in an attempt to determine the prognostic value of MK expression. Mononuclear cells were separated from samples of 50 newly diagnosed cases of AML; 10 healthy volunteers were included in this study as control group. The reverse transcription polymerase chain reaction method was used to examine the expression of MK mRNA in mononuclear cells. Midkine gene mRNA expression rate was significantly higher in AML patients when compared to control group (p < 0.001); comparing Midkine expression in patients with different clinical and laboratory findings was of no statistical significance (p > 0.05). Moreover, Midkine expression was significantly higher in patients that did not achieve complete remission compared to those who succeeded to achieve one (p < 0.001). Midkine may play an important role in the tumorigenesis of AML, and evaluation of MK expression may prove to be useful for predicting response to treatment. |
abstract_unstemmed |
Abstract Midkine (MK) is a heparin-binding growth factor and a product of a retinoic acid-responsive gene. Midkine is overexpressed in many carcinomas and thought to play an important role in carcinogenesis. However, no studies have been focused on the role of MK in AML. This study sought to evaluate the expression of MK among AML patients to explore possible correlation between MK expression and different clinicopathologic variables in an attempt to determine the prognostic value of MK expression. Mononuclear cells were separated from samples of 50 newly diagnosed cases of AML; 10 healthy volunteers were included in this study as control group. The reverse transcription polymerase chain reaction method was used to examine the expression of MK mRNA in mononuclear cells. Midkine gene mRNA expression rate was significantly higher in AML patients when compared to control group (p < 0.001); comparing Midkine expression in patients with different clinical and laboratory findings was of no statistical significance (p > 0.05). Moreover, Midkine expression was significantly higher in patients that did not achieve complete remission compared to those who succeeded to achieve one (p < 0.001). Midkine may play an important role in the tumorigenesis of AML, and evaluation of MK expression may prove to be useful for predicting response to treatment. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 |
container_issue |
3 |
title_short |
The expression of Midkine gene in patients with acute myeloid leukemia and its significance |
url |
https://dx.doi.org/10.1007/s00580-013-1680-1 |
remote_bool |
true |
author2 |
El Dahshan, Dina H. Metwally, Hassan M. El Feky, Mohamed A. |
author2Str |
El Dahshan, Dina H. Metwally, Hassan M. El Feky, Mohamed A. |
ppnlink |
559430590 |
mediatype_str_mv |
c |
isOA_txt |
false |
hochschulschrift_bool |
false |
doi_str |
10.1007/s00580-013-1680-1 |
up_date |
2024-07-04T02:29:16.782Z |
_version_ |
1803613798958891008 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR007225504</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519204820.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201005s2013 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s00580-013-1680-1</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR007225504</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s00580-013-1680-1-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Hammam, Amira A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The expression of Midkine gene in patients with acute myeloid leukemia and its significance</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Midkine (MK) is a heparin-binding growth factor and a product of a retinoic acid-responsive gene. Midkine is overexpressed in many carcinomas and thought to play an important role in carcinogenesis. However, no studies have been focused on the role of MK in AML. This study sought to evaluate the expression of MK among AML patients to explore possible correlation between MK expression and different clinicopathologic variables in an attempt to determine the prognostic value of MK expression. Mononuclear cells were separated from samples of 50 newly diagnosed cases of AML; 10 healthy volunteers were included in this study as control group. The reverse transcription polymerase chain reaction method was used to examine the expression of MK mRNA in mononuclear cells. Midkine gene mRNA expression rate was significantly higher in AML patients when compared to control group (p < 0.001); comparing Midkine expression in patients with different clinical and laboratory findings was of no statistical significance (p > 0.05). Moreover, Midkine expression was significantly higher in patients that did not achieve complete remission compared to those who succeeded to achieve one (p < 0.001). Midkine may play an important role in the tumorigenesis of AML, and evaluation of MK expression may prove to be useful for predicting response to treatment.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Midkine gene</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Acute myeloid leukemia</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gene expression</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">El Dahshan, Dina H.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Metwally, Hassan M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">El Feky, Mohamed A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Comparative haematology international</subfield><subfield code="d">London : Springer, 1991</subfield><subfield code="g">23(2013), 3 vom: 24. Jan., Seite 749-753</subfield><subfield code="w">(DE-627)559430590</subfield><subfield code="w">(DE-600)2413027-8</subfield><subfield code="x">1433-2973</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:23</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:3</subfield><subfield code="g">day:24</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:749-753</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s00580-013-1680-1</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">23</subfield><subfield code="j">2013</subfield><subfield code="e">3</subfield><subfield code="b">24</subfield><subfield code="c">01</subfield><subfield code="h">749-753</subfield></datafield></record></collection>
|
score |
7.4004726 |